Index

The index relates to the hard copy.

A

accountability and management, 76-93

see also finance

acronyms and abbreviations list, 180-182

administered finances, 99-100

special accounts, 97

administrative tribunal decisions, 84

advertising and market research, 165

age demographic of staff, 89

agency resource statements, 170-171

angioedema, 51

annual performance statement, 20-26

annual reports, 152

NBA errata, 169

NBA list of requirements, 172-178

Anti-D, 63

apheresis, 33, 34, 159

donors, 6, 40, 169

assets and asset management, 99, 102

administered items, 101

Audit Committee, 21, 79, 80, 83, 156

Australasian Society for Clinical Immunology and Allergy, 51

Australian Bleeding Disorders Registry (ABDR), 52, 54

Australian Commission on Safety and Quality in Health Care (ACSQHC), 69, 83

Australian Information Commissioner, 84

Australian National Audit Office (Auditor-General), 79, 84

Australian Public Service Commission Employee Census, 86

Australian Red Cross Blood Service (Blood Service), 11, 15, 39-41, 53, 83

data security breach, 10, 40

NMF (Blood and Blood Products) Special Account 2017, 96-97

see also fresh blood

B

balance sheet, 99

Baxalta Australia Pty Ltd, 30, 45, 160, 161, 162

Bio-Rad Laboratories Pty Ltd, 31, 45

bleeding disorders, 53, 54

blood cells, see red blood cells

blood donations, 6, 49

Blood Service, see Australian Red Cross Blood Service

BloodMove Platelets project, 67

BloodNet, 6, 10, 54, 56-58

Fate Module, 6, 51

BloodNet User Reference Group, 56

BloodSafe eLearning Australia, 68

BloodSTAR, 47-50, 56

Board, 14-16, 150-156

budget, see finance

Business Committee, 78

Business Contingency Plan, 53

C

C1 Esterase Inhibitor Concentrate, 10, 51, 162

capability reviews, 84

Chief Executive (General Manager), 3, 78, 79, 80

review of year, 8-12

classification of staff, 88-89, 90

rationalisation of levels, 92

clinical demand, see demand

clinical practice guidelines, see Patient Blood Management (PBM) Guidelines

clotting factors, see Factor VIIa; Factor VIII; Factor IX

Comcare, reportable incidents lodged with, 93

Commonwealth Ombudsman, 84

communication and promotion, 58, 66

see also information communication technology

competitive tendering and contracting, 103

conferences and sector events, 66

consultants, 104

contingency plans, 52-53

contracts, see purchasing

Corporate Plan, 21

Council of Australian Governments (COAG) Health Council, 3, 51, 53, 99

Crimson Portfolio, 54, 55

Criteria for the clinical use of intravenous immunoglobulin in Australia, 9, 47-50

CSL Behring Pty Ltd, 15, 29, 160

Australian Fractionation Agreement, 9, 34, 42

imports, 43, 45, 160, 161-163; C1 Esterase Inhibitor Concentrate, 19, 51, 162

Customer Service Charter, 84

D

data developments, 51-52

see also information communication technology

data security breach, 10, 40

Deed of Agreement, Red Cross, 11, 39-41, 53, 83

demand, 34-36, 38

variance between actual and NBA estimate, 23

diagnostic reagent products, 6, 30-31, 45

Digital Transformation Agency (DTA), 10

disability reporting, 169

discards, see wastage and discards

donor management, Blood Service, 40

E

ecologically sustainable development, 165-168

education and training, 68

staff, 85, 92

employees, 10, 79, 85, 86-93

enterprise agreement, 90

environmental performance, 165-168

establishment of NBA, 77

exempt contracts, 103

expenditure, see finance

external scrutiny, 84

F

Factor VIIa (rFVIIa), 30, 36-37

supply contracts, 11, 160

Factor VIII (rFVIII), 34, 35

Anti-Inhibitor (FEIBA), 36, 37, 160

supply contracts, 11, 160-161

Factor IX (rFIX), 34, 36

supply contracts, 11, 161

finance, 3, 96-146, 170-171

Blood Service, 11, 32, 40, 96-97

grant programs, 169

see alsopurchasing

financial assets, 99

financial statements, 106-146

audit report, 98

fractionation, see plasma and recombinant products

fraud control, 85

freedom of information, 169

fresh blood, 28, 31-34, 39-41

components supplied under contract, 159

see also Australian Red Cross Blood Service; patient blood management; platelets; red blood cells

full-time staff, 88

functions and role, 2, 14

G

gender of staff, 88-89

General Manager, see Chief Executive

governance, 10, 76-80

blood sector data and information, 52

immunoglobulin program, 9, 46-50

grant programs, 169

Grifols Australia, 30, 43, 45, 162

Guidelines for Managing Blood and Blood Product Inventory, 47

H

haemophilia and bleeding disorders, 53, 54

see also Factor VIIa; Factor VIII; Factor IX

haemovigilance, 52

hereditary angioedema, 51

horizon scanning, 59-60

human resources, 10, 79, 85, 86-93

I

immunoglobulins (Ig), 38, 52

Anti-D, 63

governance program, 9, 46-50

imported supplies, 30, 38, 43, 162-163

income, see finance

Indigenous staffing, 88

information communication technology (ICT), 54-58

BloodNet, 6, 10, 54, 56-58; Fate Module, 6, 51

BloodSafe eLearning Australia, 68

BloodSTAR, 47-50, 56

data security breach, 10, 40

Steering Committee, 79

Information Framework Agreements, 52

Information Publication Scheme statement, 169

internal audit, 80

international horizon scanning, 59-60

inventory management, 47

Blood Service, 40

CSL Australian Fractionation Agreement, 42

imported immunoglobulin, 43

imported plasma derived and recombinant products, 45

see also BloodNet; wastage and discards

J

Johnson & Johnson Medical Pty Ltd, 30, 45

judicial decisions, 84

Jurisdictional Blood Committee (JBC), 51, 54

K

key performance indicators,

see performance indicators/criteria

L

legal decisions, 84

legislation, 3, 14, 76, 77, 96

Public Governance, Performance and Accountability Act 2013, 21, 96, 104

Public Governance, Performance and Accountability Rule 2014 (PGPA Rule), 21, 85

liabilities, see assets

M

management and accountability, 76-93

see also finance

market research and advertising, 165

Medical Services Advisory Committee, 51

Ministers, 3

MyABDR portal, 54

N

National Blood Account, 96, 97

National Blood Agreement, 3, 59, 71, 76, 77

evaluations undertaken under Schedule 4, 51

National Blood and Blood Product Wastage Reduction Strategy 2013-2017, 51, 63, 65

National Blood Authority Act 2003, 3, 14, 76, 77, 96

National Blood Authority Board, 14-16, 150-156

National Blood Sector Data and Information Governance Framework, 52

National Blood Sector Data and Information Strategy and Scorecard 2013-2016, 51-52

National Blood Sector Education and Training Strategy, 68

National Blood Sector Research and Development Pilot, 71-73

National Blood Supply Contingency Plan, 52, 53

National Haemovigilance Report 2017, 52

National Immunoglobulin Governance Advisory Committee, 46

National Immunoglobulin Governance Program, 9, 46-50

National Inventory Management Framework, 23

National Managed Fund Action Plan Review, 53

National Managed Fund (Blood and Blood Products) Special Account 2017, 96-97

National Patient Blood Management Collaborative, 83

National Patient Blood Management Guidelines Implementation Strategy, 62, 63

National Policy: Access to Government Funded Immunoglobulin Products in Australia, 47

National Products and Services List, 51

National Safety and Quality Health Service Standard on Blood and Blood Products, 24, 62, 69

National Safety and Quality Health Service Standards, 69

National Service Requirements and Standards, 40

National Supply Plan and Budget, 28-38, 99

non-English speaking backgrounds, employees from, 88

non-financial assets, 99

non-ongoing staff, 89

normal immunoglobulin (NIg), 38, 163

Novo Nordisk Pharmaceuticals Pty Ltd, 30, 45, 160

O

objectives, 28-73

occupational health and safety, 92-93

Ombudsman, 84

ongoing staff, 89

online services, see information communication technology

operating result, 98-101

Blood Service, 32, 40

operational planning, 81-83

organisation and structure, 2-16, 76-80

organisation charts, 4, 76, 78, 87

Ortho-Clinical Diagnostics, 30, 45

Output Based Funding Model, 32, 40, 100

overseas horizon scanning, 59-60

P

Parliamentary committees, 84

part-time staff, 11

patient blood management, 62-64, 83

BloodSTAR, 47-50, 56

performance criteria and results, 24-26

Patient Blood Management (PBM) Guidelines, 26, 63, 64

BloodSafe eLearning Australia releases based on, 68

payroll function, 92

people management, 10, 79, 85, 86-93

performance indicators/criteria, 22-26

Australian Red Cross Blood Service, 39-40

CSL Australian Fractionation Agreement, 42

environmental performance, 166-168

imported immunoglobulin, 43

imported plasma derived and recombinant products, 45

performance pay, 92

performance statement, 20-26

Pfizer Australia Pty Ltd, 30, 45, 161

planning framework, 81-83

contingencies, 52-53

plasma and recombinant products, 28, 29, 30, 34-38

supply contracts, 11, 42-45, 160-163

supply risk mitigation, 53

see also immunoglobulins

plasma for fractionation, 9, 32, 34, 42, 159

plasma only collection centres, 40

plasmapheresis, see apheresis

platelets, 7, 33, 159

wastage, 67

Portfolio Budget Statements, 21

prices, 32, 34, 35, 159-163

procurement, see purchasing

productivity gains, 92

Project Governance Boards, 79

promotion and communication, 66

see also information communication technology

Public Governance, Performance and Accountability Act 2013, 21, 96, 104

Public Governance, Performance and Accountability Rule 2014 (PGPA Rule), 21, 85

Public Service Act 1999, 3

purchasing, 103-104, 164-165

purchasing of blood and blood product supply, 3, 11, 28-45, 159-163

C1 Esterase Inhibitor Concentrate, 10, 51, 162

contract management, 39-45

savings, 11, 32, 35; from wastage reduction, 6, 32, 67

see also inventory management

Q

Queensland, 51

R

recombinant products, see plasma and recombinant products

red blood cells, 7, 32-33, 34, 62, 159

diagnostic reagent products, 6, 30-31, 45

wastage and discards, 25, 32, 51, 65

remuneration of staff, 90-91, 92

Request for Information and Stakeholder Consultation Paper, 11

research and development, 71-73

Blood Service, 41

resource statements, 170-171

revenue, see finance

Review of Risk Management in the Blood Sector, 53

Rh D immunoglobulin, 63

risk management, 52-53

S

safe and efficient use, 24, 61-73

salary and remuneration, 90-91, 92

satisfaction with Blood Service, 40

savings, 11, 32, 35

from wastage reduction, 6, 32, 67

sector monitoring, 59-60

security of supply, see supply

Senior Executive Management, 79, 80

Seqirus Pty Ltd, 45

Service Charter, 84

small business, procurement initiatives to support, 104, 164

South Australia, 67

special accounts, 96-97

Specialist Working Groups, 49

staff, 10, 79, 85, 86-93

stakeholders, 70

engagement program, 15

standards, 52, 68

Blood Service, 40

National Safety and Quality Health Service, 24, 62, 69

Statement on national stewardship expectations for the supply of blood and blood products, 63

supply, 11, 28-60, 159-163

performance criteria and results, 22-24

supply chain management, see inventory management

T

tenders, see purchasing

training, see education and training

tribunal decisions, 84

V

values, 87

W

wastage and discards, 25, 32, 51, 63

BloodNet Fate Module, 6, 51

platelets, 67

red blood cells, 25, 32, 51, 65

website services, see information communication technology

Western Australia, 58

whole blood, 33, 34, 40, 159

work health and safety, 92-93